Beijing Sipo Biotechnology

Beijing Sipo Biotechnology is a pioneering Chinese biotechnology company focused on the research and development of gene therapies and oncolytic viruses for oncology. The company gained international recognition for developing Oncorine (H101), an E1B-deleted oncolytic adenovirus that became the first of its kind to be approved by a regulatory agency in 2005. Sipo's core expertise lies in engineering viral vectors to selectively replicate in and lyse cancer cells, particularly those with p53 pathway deficiencies. Based in Beijing, the firm operates at the intersection of molecular biology and clinical oncology to provide innovative treatments for refractory solid tumors. The company's successful commercialization of Oncorine marked a significant milestone in the global history of virotherapy. Beijing Sipo continues to maintain its focus on recombinant viral technologies and collaborative efforts to expand the reach of gene-based medicines.